- Home
- NCZ vs QTRX Comparison
NCZ vs QTRX Comparison
Compare NCZ & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- QTRX
- Stock Information
- Founded
- NCZ 2003
- QTRX 2007
- Country
- NCZ United States
- QTRX United States
- Employees
- NCZ N/A
- QTRX N/A
- Industry
- NCZ Finance Companies
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- NCZ Finance
- QTRX Industrials
- Exchange
- NCZ Nasdaq
- QTRX Nasdaq
- Market Cap
- NCZ 228.3M
- QTRX 233.5M
- IPO Year
- NCZ N/A
- QTRX 2017
- Fundamental
- Price
- NCZ $12.36
- QTRX $6.38
- Analyst Decision
- NCZ
- QTRX Buy
- Analyst Count
- NCZ 0
- QTRX 5
- Target Price
- NCZ N/A
- QTRX $15.60
- AVG Volume (30 Days)
- NCZ 533.0K
- QTRX 770.6K
- Earning Date
- NCZ 01-01-0001
- QTRX 05-12-2025
- Dividend Yield
- NCZ 12.16%
- QTRX N/A
- EPS Growth
- NCZ N/A
- QTRX N/A
- EPS
- NCZ N/A
- QTRX N/A
- Revenue
- NCZ N/A
- QTRX $135,688,000.00
- Revenue This Year
- NCZ N/A
- QTRX N/A
- Revenue Next Year
- NCZ N/A
- QTRX $16.52
- P/E Ratio
- NCZ N/A
- QTRX N/A
- Revenue Growth
- NCZ N/A
- QTRX 7.71
- 52 Week Low
- NCZ $2.50
- QTRX $4.05
- 52 Week High
- NCZ $3.15
- QTRX $19.18
- Technical
- Relative Strength Index (RSI)
- NCZ 62.67
- QTRX 61.24
- Support Level
- NCZ $12.24
- QTRX $4.94
- Resistance Level
- NCZ $12.36
- QTRX $7.03
- Average True Range (ATR)
- NCZ 0.11
- QTRX 0.43
- MACD
- NCZ -0.00
- QTRX 0.19
- Stochastic Oscillator
- NCZ 79.31
- QTRX 73.05
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.